Patents by Inventor Paul Gellert

Paul Gellert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dendrimer formulations
    Patent number: 12115174
    Abstract: Disclosed are pharmaceutical compositions comprising a lyophilized compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and methods of using the same for treating cancer.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: October 15, 2024
    Assignee: AstraZeneca AB
    Inventors: Paul Gellert, Kathryn Hill, Richard Storey
  • DENDRIMER FORMULATIONS
    Publication number: 20220273677
    Abstract: Disclosed are pharmaceutical compositions comprising a lyophilized compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and methods of using the same for treating cancer.
    Type: Application
    Filed: August 15, 2019
    Publication date: September 1, 2022
    Inventors: Paul GELLERT, Kathryn HILL, Richard STOREY
  • Pharmaceutical composition
    Publication number: 20070141141
    Abstract: An immediate release pharmaceutical composition comprising 4-(3?-chloro-4?-fluoroanilino)-7-methoxy-6-(3-mor-pholinopropoxy)quinazoline or a pharmaceutically-acceptable salt thereof (the Agent); a water-soluble acid; and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The claimed compositions inhibit the rate of precipitation of the Agent from solution and/or provide enhanced solubilisation of the agent at pH levels similar to those of the upper GI tract. The claimed compositions are expected to be useful in reducing inter-patient and/or intra-patient variability in exposure to the Agent.
    Type: Application
    Filed: July 27, 2004
    Publication date: June 21, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Nicola Bateman, Paul Gellert, Marcel De Matas, Alison Potts
  • Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
    Publication number: 20050163835
    Abstract: A pharmaceutical composition comprising 4-(3?-chloro-4?-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent) and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The water-soluble cellulose ether or ester of a water-soluble cellulose ether present in the composition inhibits the rate of precipitation of the Agent from solution.
    Type: Application
    Filed: February 24, 2003
    Publication date: July 28, 2005
    Applicant: AstraZeneca AB
    Inventors: Paul Gellert, Marcel De Matas, Michael Parker
  • Biodegradable implant comprising a polylactide polymer and a lh-rh analogue
    Publication number: 20050019367
    Abstract: A monolithic implant comprising a biodegradable polyester and a luteinizing hormone releasing hormone (LH-RH) analogue. The implant provides continuous release of the LH-RH analogue over a period of six months when the implant is placed in an aqueous physiological-type environment.
    Type: Application
    Filed: September 6, 2002
    Publication date: January 27, 2005
    Inventors: Jonathan Booth, Rodney Kittlety, Paul Gellert